nach oben

Erschienen in:

22.03.2021 | Magenkarzinom | Zertifizierte Fortbildung

Innovative Behandlungsansätze

Therapie von Tumoren des Magens und des Ösophagus - aktueller Stand

verfasst von: Michael Masetti, Priv.-Doz. Dr. med. Sylvie Lorenzen

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Auszug

Therapeutisch sind Adenokarzinome des Magens und des ösophagogastralen Übergangs nach wie vor eine große Herausforderung. Aktuell zeichnen sich neue Behandlungsoptionen ab, welche die Therapie zukünftig deutlich verbessern könnten. Lesen Sie in diesem Beitrag, welche Innovationen das sind - und wie der Behandlungsstandard derzeit (noch) aussieht. …

Moehler M et al. S3- Leitlinie Magenkarzinom - Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs - Lang-version 2.0 - August 2019. AWMFRegisternummer: 032/009OL. Z Gastroenterol. 2019;57(12):1517-632

Cunningham D et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20

Al-Batran SE et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cis-platin and epirubicin for locally advanced, resectable gastric or gastrooesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-57

[AWMF S3-Leitlinie Magenkarzinom Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs Langversion 2.0 - August 2019. https://www.awmf.org/leitlinien/detail/ll/032-009OL.html abgerufen am 25. Januar 2021.

Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy: First results of the CheckMate 577 study. Ann Oncol. 2020;31(suppl_4):S1142-S1215

Smyth E et al. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front Oncol. 2020;9:1320

Al-Batran SE et al. Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK. J Clin Oncol. 2019;37:15_suppl

Bang YJ et al. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019;15(9):943-52

Institut, R.K., Krebs in Deutschland 2013/2014. http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017/krebs_in_deutschland_2017.pdf, 11. Auflage 2017; abgerufen am 25. Januar 2021

10.

Dank M et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008;19(8):1450-7

11.

Guimbaud R et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study [published correction appears in J Clin Oncol. 2015;33(12):1416]. J Clin Oncol. 2014;32(31):3520-26

12.

Al-Batran SE et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2008;19(11):1882-7

13.

Al-Batran SE et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur J Cancer. 2013;49(4):835-42

14.

Van Cutsem E et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-84

15.

Rüschoff J et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637-50

16.

Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010;376(9749):1302]. Lancet. 2010;376(9742):687-97

17.

Moehler M et al. S3-Leitlinie "Magenkarzinom" - Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs (AWMF-Regist.-Nr. 032-009-OL) [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol. 2011;49(4):461-531

18.

Lordick F et al; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50-v57

19.

Makiyama A et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38(17):1919-27

20.

Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study. Ann Oncol. 2020;31 (suppl_4):S841-S873

21.

Janjigian YY et al. A phase Ib/II, multicenter, open-label, dose-escalation and dose- expansion study evaluating trastuzumab deruxtecan (T-DXd; DS- 8201) monotherapy and combinations in patients with HER2- overexpressing gastric cancer (DESTINY-Gastric03). Ann Oncol. 2020;31 (suppl_4):S841-S873

22.

Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-39

23.

Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-35

24.

Van Hagen P et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-84

25.

Tabernero J et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study [published correction appears in Lancet Oncol. 2015;16(6):e262]. Lancet Oncol. 2015;16(5):499-508

26.

Hironaka S et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438-44

27.

Shitara K et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2018;19(12):e668]. Lancet Oncol. 2018;19(11):1437-48

28.

Eto K et al. Treatment strategy for metastatic gastric cancer in Japan. J Cancer Metastasis Treat. 2018;4:23

29.

Kang YK et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO- 4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461-71

30.

Ajani JA et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw 2015;13(2):194-227

31.

Shitara K et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123-33

32.

Tabernero J et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. J Clin Oncol. 2019;37:18 (Suppl):LBA4007

33.

Moehler M et al. Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1l) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/ esophageal adenocarcinoma (EAC): First results of the Check-Mate 649 study. Ann Oncol. 2020;31(suppl_4):1142-215

34.

Boku N et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION- 4 (ONO-4538-37) study. Ann Oncol. 2020;31(suppl_4):S1142-S1215

35.

Kato K et al. LBA8_PR - Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31 (suppl_4):S1142-S1215

36.

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9

37.

Kim ST et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449-1458

38.

39.

Kang YK et al. Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION- 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461-71

40.

Fuchs CS et al. The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061. Journal of Clinical Oncology. 2020;38(15_suppl):4512-4512

Titel: Innovative Behandlungsansätze
Therapie von Tumoren des Magens und des Ösophagus - aktueller Stand
verfasst von: Michael Masetti
Priv.-Doz. Dr. med. Sylvie Lorenzen
Publikationsdatum: 22.03.2021
Verlag: Springer Medizin
Schlagwörter: Magenkarzinom
Zytostatische Therapie
Magenkarzinom
Adenokarzinom des ösophagogastralen Übergangs
Adenokarzinom des ösophagogastralen Übergangs
Ramucirumab
Trastuzumab
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 3/2021
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-021-8575-0

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Hämatoonkologische Highlights von den TZM Essentials

Invasive Aspergillosen wirksam bekämpfen

Nach ICI kommt es auf die Sequenz an

Wer ist für medizinische Falschinformationen empfänglich?

B-Zell-Depletion stellt keine Kontraindikation für die Impfung dar!

Daten zum neuen Behandlungsstandard Pembrolizumab beim MSI-H-mCRC